Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland PharmaNSE:GLAND +2.55%81 Days Payable is 121.88 as of Jun. 2026, which is 6% above its 10-year median of 115.14. GuruFocus rates NSE:GLAND with a GF Score™ of 81/100 and a GF Value™ of ₹2,196.94 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Gland Pharma ranks better than 72.32% on this metric.
The historical data trend for Gland Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gland Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a Days Payable of 121.88 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gland Pharma and its competitors. This is near median its historical median of 115.14. Over the past decade, Gland Pharma's Days Payable has ranged from 74.34 to 161.20. According to the industry distribution chart, Gland Pharma ranks #256 out of 925 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Gland Pharma's Days Payable too high?
Gland Pharma's current Days Payable of 121.88 is near median its 10-year median of 115.14. Over the past 10 years, this metric has ranged from a low of 74.34 to a high of 161.20. The Drug Manufacturers industry median Days Payable is 89.79. Gland Pharma's value of 121.88 is 35.7% above this industry median. Based on the distribution chart, Gland Pharma ranks #256 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #256 out of 925 companies for Days Payable. This puts Gland Pharma in the upper half of its industry. The industry median Days Payable is 89.79. Gland Pharma's value of 121.88 is 35.7% above this benchmark. Historically, Gland Pharma's own Days Payable has ranged from 74.34 to 161.20 over the past decade. While the company's 10-year median is 115.14 vs. the industry median of 89.79, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Days Payable of 121.88 is 35.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Days Payable is 121.88, which is near median its own 10-year median of 115.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,196.94, compared to a current price of ₹2,924.40 — trading 33.1% above its estimated fair value. The current Days Payable is 121.88, which is near median its 10-year median of 115.14 and 35.7% above the Drug Manufacturers industry median of 89.79. Gland Pharma's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Days Payable is 121.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,924.40 is trading 33.1% above its estimated GF Value™ of ₹2,196.94.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Days Payable: 121.88 (near median its 10-year median of 115.14)
GF Value™: ₹2,196.94 vs. price of ₹2,924.40 (33.1% above fair value)
Industry Position: 35.7% above the Drug Manufacturers median (#256 of 925)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
81GF Score
Get the complete analysis for NSE:GLAND
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
